Elekta nets FDA OK for VMAT update

Justine Varieur Cadet | | Health Imaging | Oncology Imaging
Elekta has received FDA 510(k) clearance for a volumetric modulated arc therapy (VMAT) enhancement to Monaco, its radiation therapy treatment planning solution.

According to the Stockholm, Sweden-based company, the Monaco system introduces a set of tools to make the treatment planning process easier. Its intensity modulated radiotherapy (IMRT) treatment planning system features constrained optimization and dose calculation algorithms.

Monaco has been available for use clinically for the past two years for step-and-shoot IMRT planning. The product was developed in cooperation with Eberhard Karls University Tuebingen in Germany.

Justine Varieur Cadet

Related Content

MRI-first approach could allow many to safely forego prostate biopsy
MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer
Breast cancer only visible via MRI is often less aggressive

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.